Nurse Practitioner Exam Questions and Answers 100% verified 2026

Nurse Practitioner Exam Questions
and Answers 100% verified 2026
PrimaryMpreventionM-MAnswerMpreventMtheMonsetMorMacquisitionMofMaMgivenMdisease.M



educationMandMcounseling



theMmostMeffectiveMformMofMhealthcare.



SecondaryMpreventionM-
MAnswerMtoMidentifyMandMtreatMasymptomaticMpersonsMwhoMhaveMriskMfactorsMforMa
MgivenMdiseaseMorMinMpreclinicalMdisease.M



screening,M

BPMforMHTN

LipidMProfileMforMHLD



TertiaryMpreventionM-MAnswerMmanagementMofManMestablishedMdisease.M

minimizeMdisease



medicationsMandMlifestyleMmodificationMtoMnormalizeM



aimedMatMimprovingMorMminimizingMdisease-relatedMsymptoms.



ActiveMimmunityMisMdefinedMasM-
MAnswerMresistanceMdevelopedMinMresponseMtoManMantigen.



WhichMofMtheMfollowingMstatementsMbestMdescribesMzanamivirM(Relenza)MorMoseltamivir
M(Tamiflu)MuseMinMtheMcareMofMpatientsMwithMorMatMriskMforMinfluenza?M-
MAnswerMInitiationMofMtherapyMearlyMinMacuteMinfluenzaMillnessMcanMhelpMminimizeMth
eMseverityMofMdiseaseMwhenMtheMillnessMisMcausedMbyMaMnonresistantMviralMstrain.



PreventiveMServicesMRecommendedMbyMtheMUSPSTFM-MAnswerM

,PreventiveMServicesMRecommendedMbyMtheMUSPSTFM2M-MAnswerM



InManMimmunocompetentMadult,MtheMlengthMofMincubationMforMtheMinfluenzaMvirusMisM
onMaverage:M-MAnswerM1-4Mdays



AdultsMpassMtheMillnessMonM1MdayMbeforeMtheMonsetMofMsymptomsMandMcontinueMto
MremainMinfectiousMforMapproximatelyM5MdaysMafterMtheMonsetMofMtheMillness.MChildre
nMremainMinfectiousMforM10MorMmoreMdaysMafterMtheMonsetMofMsymptomsMandMcanM
shedMtheMvirusMbeforeMtheMonsetMofMsymptoms.MPeopleMwhoMareMimmunocompromise
dMcanMremainMinfectiousMforMupMtoM3Mweeks.



InfluenzaMprotectionMoptionsMforMaM62-year-
oldMmanMwithMhypertension,Mdyslipidemia,MandMtypeM2MdiabetesMmellitusMincludeMrecei
ving:M-
MAnswerMtrivalentMinactivatedMvaccineM(TIV)MinMstandardMdoseMviaMintramuscularMinjecti
on.



ThisMisMtheMtypicalM"fluMshot."MAMquadrivalentMinactivatedMvaccineMisMalsoMavailable.



injectedMisMnotMliveMbutMtheMnasalMsprayMis



WhichMofMtheMfollowingMshouldMnotMreceiveMvaccinationMagainstMinfluenza?

A.MaM19Myear-oldMwithMaMhistoryMofMhive-formMreactionMtoMeatingMeggs

B.MaM24-year-oldMwomanMwhoMisM8MweeksMpregnantM

C.MaM4-month-oldMinfantMwhoMwasMbornMatM32MweeksMofMgestation

D.MaM28-year-oldMwomanMwhoMisMbreastfeedingMaM2MweekMold.M-MAnswerMc



allMmembersMofMtheMpopulationMageM6MmonthsMandMolderMshouldMreceiveMannualMim
munizationMagainstMseasonalMinfluenza.



thoseMwithManMeggMallergyMthatMisMonlyMhivesMshouldMbeMgivenMtheMvax



AMhealthyM6-year-
oldMgirlMpresentsMforMcare.MHerMparentsMrequestMthatMsheMreceiveMvaccinationMforMinf
luenzaMandMreportMthatMsheMhasMnotMreceivedMthisMvaccineMinMtheMpast.MHowMmany
MdosesMofMinfluenzaMvaccineMshouldMsheMreceiveMthisMfluMseason?

,A.1MB.2MC.3MD.4M-MAnswerMb



AllMchildrenMagedM6MmonthsMtoM8MyearsMwhoMreceiveMaMseasonalMinfluenzaMvaccineM
forMtheMfirstMtimeMshouldMreceiveM2MdosesMspacedM≥4MweeksMapart.



highMriskMpopulationsMthatMneedMfluMvaxM-
MAnswerM•MAllMchildrenMagedM6MthroughM59Mmonths.

•MAdultsMandMchildrenMwhoMhaveMchronicMpulmonaryM(includingMasthma)MorMcardiovasc
ularM(exceptMisolatedMhypertension),Mrenal,Mhepatic,Mneurological,Mhematologic,MorMmeta
bolicMdisordersM(includingMdiabetesMmellitus).MIndividualsMageM50MyearsMofMageMandMol
der.

•MPersonsMwhoMhaveMimmunosuppressionM(includingMimmunosuppressionMcausedMbyMme
dicationsMorMbyMHIVMinfection).

•MWomenMwhoMareMorMwillMbeMpregnantMduringMtheMinfluenzaMseason.

•MChildrenMandMadolescentsM(agedM6MmonthsM-M18Myears)MwhoMareMreceivingMlong-
termMaspirinMtherapyMandMwhoMmightMbe

atMriskMforMexperiencingMReye'sMsyndromeMafterMinfluenzaMvirusMinfection.

•MResidentsMofMnursingMhomesMandMotherMlong-termMcareMfacilities.

•MAmericanMIndians/AlaskaMNatives.

•MPersonsMwhoMareMmorbidlyMobeseM(BMIM≥40)Mkg/m2.

•MPeopleMwhoMliveMwithMorMcareMforMthoseMatMhighMriskMforMcomplicationsMfromMfl
u,Mincluding:

•MHealthcareMworkers.

•MHouseholdMcontactsMofMpersonsMwithMmedicalMconditionsMthatMputMthemMatMhighMr
iskMforMcomplicationsMfromMtheMflu.

•MHouseholdMcontactsMandMoutMofMhomeMcaregiversMofMchildrenMagedM≤59MmonthsMa
ndMadultsMagedM≥50Myears,MwithMpar-

ticularMemphasisMonMvaccinatingMcontactsMofMchildrenMlessMthanM6MmonthsMofMage.M(
TheseMchildrenMareMtooMyoungMtoMbeMvaccinated.)



LAIVMisMapprovedMfor___M-
MAnswerMLAIVMisMapprovedMforMuseMinMhealthyMpeopleMagesM2MtoM49MyearsMold



ItMisMnotMforMpatientsMwithMaMhealthMconditionMthatMplacesMthemMatMhighMriskMfor
McomplicationsMfromMinfluenza,MincludingMchronicMheartMdisease,MchronicMlungMdis-
MeaseMsuchMasMasthmaMorMreactiveMairwaysMdisease,MdiabetesMorMkidneyMfailure,Mand

, Mimmunosuppression;MchildrenMorMadolescentsMreceivingMlong-termMhigh-
doseMaspirinMtherapy;MpeopleMwithMaMhistoryMofMGuillain-
BarréMsyndrome;MpregnantMwomen;MandMpeopleMwithMaMhistoryMofMallergyMtoManyMof
MtheMcomponentsMofMLAIV.MAdverseMeffectsMofMLAIVMincludeMnasalMirritationMandMdisc
harge,MmuscleMaches,MsoreMthroat,MandMfever.



FDAMapprovedMantiviralMdrugsMforMfluM-
MAnswerMInMtheMUnitedMStates,MfourMantiviralMdrugsMareMapprovedMbyMtheMFoodMan
dMDrugMAdministrationM(FDA)MforMuseMagainstMinfluenza:MamantadineM(Symmetrel),Mrima
ntadineM(Flumadine),MzanamivirM(Relenza),MandMoseltamivirM(Tamiflu).



whichMfluMdrugsMareMonlyMforMinfluenzaMAMandMwhatMareMtheMnewMreccsMforMthem
M-MAnswerMamantadineM(Symmetrel),MrimantadineM(Flumadine)



highMlevelsMofMresistanceMofMinfluenzaMAMvirusesMtoMamantadineMandMsimilarMmedicati
ons.MBecauseMofMthisMsignificantMlevelMofMresistance,MamantadineMandMrimantadineMare
MnoMlongerMrecommendedMbyMtheMCDCMforMtheMtreatmentMofMinfluenza.



adverseMaffectsMofMtheM2MmainMfluMantiviralMdrugsM-
MAnswerMZanamivirMisMinhaledMandMcanMcauseMbronchospasm,MespeciallyMinMpatientsM
withMasthmaMorMotherMchronicMlungMdisease.M



TheMadverseMeffectsMofMoseltamivirMareMlargelyMgastrointestinal;MtheMriskMofMnauseaMa
ndMvomitingMisMsignificantlyMreducedMifMtheMmedicationMisMtakenMwithMfood.



WhenMconsideringManMadult'sMriskMforMmeasles,Mmumps,MandMrubellaM(MMR),MtheMNP
MconsidersMtheMfollowing:MA.MPatientsMbornMbeforeM1957MhaveMaMhighMlikelihoodMof

immunityMagainstMtheseMdiseasesMbecauseMofMaMhistory

ofMnaturalMinfection.

B.MConsiderableMmortalityMandMmorbidityMoccurMwithMall

threeMdiseases.

C.MMostMcasesMinMtheMUnitedMStatesMoccurMinMinfants.

D.MTheMuseMofMtheMMMRMvaccineMisMoftenMassociatedMwithMprotractedMarthralgia.M-
MAnswerMA



TheMMMRMvaccineMcontainsMliveMbutMweakenedM(attenuated)Mvirus.M